Costa Tiago, Taylor Abigail, Black Francesca, Hill Sean, McAllister-Williams R Hamish, Gallagher Peter, Watson Stuart
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Northern Centre for Mood Disorders, Newcastle University, Newcastle upon Tyne, UK; and Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
BJPsych Open. 2023 Jun 14;9(4):e106. doi: 10.1192/bjo.2023.68.
Autonomic nervous system (ANS) dysregulation might be relevant to the pathophysiology of fatigue and cognitive impairment in depression and perhaps should be considered when making prescribing decisions.
To determine the relationship of self-reported ANS symptoms with fatigue, cognition and prescribed medication in people with a diagnosis of depression, in comparators without depression but with other mental health, neurodevelopmental or neurodegenerative disorders (active controls) and in healthy controls.
Cross-sectional analysis of an opportunistic sample from England. Self-reported data were collected on demographics, diagnosis, medication, ANS symptoms (Composite Autonomic Symptom Scale-31, COMPASS-31) and fatigue (Visual Analogue Scale for Fatigue, VAS-F). A subsample completed cognitive tests (THINC-it), including the subjective Perceived Deficits Questionnaire five-item version (PDQ-5). Spearman's correlation and mediation models were used to explore the relationship between COMPASS-31, VAS-F and PDQ-5 scores.
Data were obtained for 3345 participants, 22% with depression. The depression group had significantly ( < 0.01) more severe autonomic dysregulation as measured by COMPASS-31 scores (median 30) than active (median 23) and healthy controls (median 10). The depression group had significantly higher symptom severity ( < 0.01) than both control groups on the VAS-F and PDQ-5. Overall, there was a significantly positive correlation ( < 0.01) between COMPASS-31, VAS-F scores (Spearman's rho = 0.44) and PDQ-5 scores ( = 0.56). COMPASS-31 scores mediated greater symptom severity on the VAS-F and PDQ-5 for those with depression. COMPASS-31 scores remained significantly different between the depression group and both control groups independently of medication.
People with a diagnosis of depression report worse fatigue and cognition than active and healthy comparators; this appears to be mediated by ANS dysregulation.
自主神经系统(ANS)功能失调可能与抑郁症中疲劳和认知障碍的病理生理学相关,在做出处方决策时或许应予以考虑。
确定在诊断为抑郁症的患者、无抑郁症但患有其他心理健康、神经发育或神经退行性疾病的对照者(活性对照)以及健康对照者中,自我报告的自主神经系统症状与疲劳、认知及所开药物之间的关系。
对来自英格兰的一个机会性样本进行横断面分析。收集了关于人口统计学、诊断、药物、自主神经系统症状(复合自主神经症状量表-31,COMPASS-31)和疲劳(疲劳视觉模拟量表,VAS-F)的自我报告数据。一个子样本完成了认知测试(THINC-it),包括主观感知缺陷问卷五项版(PDQ-5)。使用Spearman相关性和中介模型来探索COMPASS-31、VAS-F和PDQ-5得分之间的关系。
获得了3345名参与者的数据,其中22%患有抑郁症。通过COMPASS-31得分(中位数30)测量,抑郁症组的自主神经功能失调明显(<0.01)比活性对照(中位数23)和健康对照(中位数10)更严重。抑郁症组在VAS-F和PDQ-5上的症状严重程度明显高于两个对照组(<0.01)。总体而言,COMPASS-31、VAS-F得分(Spearman相关系数rho = 0.44)和PDQ-5得分(= 0.56)之间存在显著正相关(<0.01)。COMPASS-31得分介导了抑郁症患者在VAS-F和PDQ-5上更严重的症状。无论药物如何,抑郁症组与两个对照组之间的COMPASS-31得分仍存在显著差异。
诊断为抑郁症的患者报告的疲劳和认知比活性对照和健康对照更差;这似乎是由自主神经系统功能失调介导的。